fda bpc 157 category 2 bulk drug substance list Peptide Update: Removals Explained FDA considers adding a dozen
FDA considers adding a dozen peptides to its bulk drug compounding list RAPS BPC 157 Legal Status: FDA Regulations and Compounding BREAKING: The FDA just reversed theIR 2023 peptide ban. 12 peptides were just pulled from the Category 2 restricted list: 1. BPC 157 2. Thymosin beta 4 fragment (TB 500) 3. Epitalon 4. GHK Cu (injectable) The experts will take votes on whether the FDA should allow seven popular peptides to be added to a list of substances that are safe for compounding by pharmacies. BPC 157 FDA advisers back first four of seven unapproved peptides under review for looser rules Reuters
Pay in 4 interest-free payments of $6.83 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7


